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ABSTRACT:
Pemphigus vulgaris (PV) is a chronic autoimmune blistering disease affecting mucous membranes 
and the skin. Rituximab (RTX), a monoclonal antibody against CD20, has been approved by FDA for 
the treatment of adults with moderate to severe PV. A 42-year-old Indian woman, with refractory oral 
PV presented to our clinic with painful erosions and ulcers of her oral mucosa. She was treated with 
available evidence based immunosuppressants with limited success over a period of 8 years. RTX was 
given observing the lymphoma protocol. Her symptoms improved dramatically after the first month 
of RTX with sustained resolution on low doses of prednisone, mycophenolate mofetil and no 
significant new lesions appearing to date. Her quality of life improved significantly. RTX seemed an 
effective treatment for refractory oral PV. 
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INTRODUCTION: Pemphigus vulgaris (PV) is a 
chronic autoimmune blistering disease affecting 
mucous membranes and the skin in which specific 
antibodies directed against desmoglein Dsg3 and 
Dsg1 are detected. These are transmembrane proteins 
found on the cell-cell junctions of keratinocytes (called 
as desmosomes) that maintain the tissue and cell 
integrity. If the autoantibodies are against Dsg3, the 
disease manifests as oral lesions. The auto-antibodies 
against Dsg1 presents with cutaneous lesions. 
However, it is not uncommon to have patients 
presenting with oral lesions and then progressing 
with generalized skin lesions. The standard first-line 
and evidence based treatment of PV are systemic 
corticosteroids with adjuvant immunosuppressive 
agents (azathioprine, mycophenolate mofetil). 
However, some cases are refractory to the latter 
treatments or suffer from side effects of the drugs or 
are not eligible due to other co-morbid systemic 
1diseases (i.e. diabetes) . Rituximab (RTX) is a chimeric 
human-mouse monoclonal antibody against the 
transmembrane antigen CD20 which is expressed on 
1B lymphocytes . After the binding of RTX to CD20, 
normal and pathogenic B-cells are depleted; whereas 
1terminally differentiated plasma cells are spared . 
RTX is approved for the treatment of CD20+ B-cell 
non-Hodgkin  lymphoma,  CD20+ chronic  
lymphocytic leukemia and Rheumatoid arthritis 
(RA) unresponsive to TNFα antagonists. RTX has 
been reported to be used off-label for autoimmune 
diseases as well following its successful use for 
paraneoplastic pemphigus associated with B-cell 
2non-Hodgkin lymphoma . RTX has recently been 
approved by the FDA (2018, USA) for the treatment of 
3adults with moderate to severe PV . According to the 
European guideline, RTX is indicated for patients 
who remain dependent on more than 10 mg 
prednisolone combined with an immunosuppressive 
4adjuvant . The International Bullous Disease 
Consensus Group has also recently recommended 
the use of RTX and corticosteroids as first line therapy 
5options for moderate to severe PV . We document the 
first case of refractory oral PV in South Africa that was 
successfully treated with RTX.
CASE:
In 2012, a 42-year-old Indian woman presented to the 
Charlotte Maxeke Johannesburg Academic Hospital 
in Johannesburg, Gauteng Outpatient Clinic with 
painful ulcers affecting her oral mucosa of six-month 
duration. She had no systemic diseases (diabetes, 
thyroid disease) and was not on any systemic 
medication. She was diagnosed with oral PV at the 
Nelson Mandela Medical School UKZN, Natal in 
2006,  confirmed on tissue histology and  
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immunofluorescence findings. Intralesional steroids, 
monthly intravenous pulses of methylprednisolone, 
IV and oral cyclophosphamide and intravenous 
immunoglobulin (IVIG) induced lessening of her oral 
symptoms but sustained improvement or remission 
was never achieved. She was maintained on 
combination systemic therapy of low dose 
prednisone, mycophenolate mofetil (MMF) with 
tetracycline and nicotinamide on a continuos basis. 
She moved provinces and presented to us with deep 
painful erosions and ulcers on her tongue, buccal 
mucosae and soft and hard palate. She had no skin, 
scalp, nail and dental changes. Her blood pressure 
was 120/80 mmHg and physical examination was all 
normal. Her disease affected her speech, diet and her 
personal quality of life. Her mucosal lesions were 
consistent with a diagnosis of oral PV, and we 
o b t a i n e d  t h e  h i s t o p a t h o l o g y  a n d  
immunohistochemistry report from the previous 
institution. The biopsies were not repeated. 
Endoscopy at the Gastroenterology Unit revealed 
oesophageal erosions and cricopharyngeal 
ulcerations. We continued her previous treatment, 
and added cyclosporine (100 mg bd) both systemically 
and as mouth washes intermittently, and maintained 
her on high doses of both MMF (2g/daily) and 
systemic steroids (10 mg/daily). Despite these 
evidence based therapeutic interventions; she did not 
achieve a clinical state of remission. She lived on 
liquidized food and had a poor social life. She stopped 
working because of the morbidity of oral PV and her 
personal life suffered. In November 2016 with a 
diagnosis of refractory oral mucosa dominant PV, we 
obtained permission from her insurer to use RTX.  
2RTX was given at 375 mg/m  body surface area weekly 
over 4 consecutive weeks in combination with 
prednisolone (20 mg/day) and MMF (2 g/day) using 
the lymphoma protocol. She complained of mild flu 
like symptoms during the infusion which resolved 
spontaneously. She had no serious adverse events 
during or after the treatment. Her blood count, 
erythrocyte sedimentation rate (ESR) and monitoring 
of her liver and kidney functions were normal. Her 
oral lesions improved dramatically after the first 
month of RTX with no significant new blisters, ulcers 
or erosions appearing to date (Figures 1 and 2). The 
CD19+B lymphocyte counts 1 month and 1 year after 
the RTX treatment was zero and 272 cell/uL (78-899 
cell/uL) respectively. Unfortunately anti-Dsg 
antibody levels were not done prior to this treatment. 
During the 20-month follow-up period, she remained 
in remission without any need for a second course of 
RTX. She is being maintained on lower systemic 
prednisolone (5mg/day) and MMF(500mg/day). She 
now eats solid foods and enjoys a normal social life.
Figure 1: Oral ulcerations located on her tongue, both buccal mucosae and the soft and hard palate
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Figure 2: Significant improvement one month after the treatment
DISCUSSION:
PV is a lifelong autoimmune blistering disorder which 
needs complex interventions directing multiple 
pathogenic pathways. Oral mucosal ulcerations are 
6frequently the site of initial presentation of PV . Due to 
the chronic and recalcitrant nature of the disease, our 
pat ient  had to be treated with mult iple  
immunosuppressive drug combinations with little 
effect on disease control, and RTX was the only 
eventual treatment that induced a state of remission. 
Since the optimal dosing regimen of RTX in 
autoimmune blistering diseases is not known, it has 
been used either with rheumatoid arthritis protocol 
(2x1000mg-2 weeks apart) or lymphoma protocol (4x 
375mg/m2-1 week apart). In two systematic reviews, 
the lymphoma protocol showed better clinical 
7,8outcomes and a lower relapse risk . We therefore 
chose the lymphoma protocol to which she responded 
successfully. Ahmed and Shetty reviewed the results 
of 499 patients with all forms of treatment refractory 
PV who had been treated with RTX. Clinical remission 
was observed in 90-95% of patients within 6 weeks, 
and complete resolution was observed within 3 to 4 
7months . According to Tavakolpour et al, the majority 
of patients responded well to RTX therapy with an 
expected relapse following 6 to 10 months after the 
9therapy . Ahmed and Shetty also reported the 
7 10incidence of relapse to be 50-80% . Similarly, Kim et al  
also observed a relapse rate of 76% with a median time 
of 17 months. In PV, recurrences might be due to 
reappearance of pathogenic autoantibody producing 
B-cells which could be hidden in immune privileged 
11sites, rather than hematopoietic stem cell recovery . 
Therefore some authors favor maintenance dosing to 
12prolong remission and prevent recurrences . Other 
researchers however refute this approach and 
suggest that further infusions should be saved just for 
13the refractory recurrences . It was reported that 
relapse was associated with CD19+B-cell  
repopulation, low CD4+T-cell count and positive 
anti-Dsg1 and Dsg3 testing. These parameters were 
suggested for predicting relapse after RTX 
14 15treatment . Vinay et al  reported three oral refractory 
PV patients, who received intralesional RTX and 
showed clinical remission  at 1 and 16 weeks. During 
follow-up periods of 6 months, only one patient 
relapsed, and no serious adverse effects were 
15recorded . One should keep in mind that RTX 
treatment showed a high relapse rate, and therefore 
intralesional RTX injection could be a good option for 
our patient in case of relapse. However, 20-month 
after the RTX ‘treatment,’ our patient remains in 
remission and her follow-up CD19+B-cell count one-
year later is within normal range. The long-term 
remission in our case is most probably achieved by 
using the lymphoma protocol and maintenance of 
conventional immunosuppressants using low 
dosages.
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The most common side effects of RTX therapy is 
bacterial and viral infections which could lead to 
7death . Serious adverse effects (i.e. infection and 
septicemia) were reported to be seen in 4.8% and 2.1% 
of the patients in the lymphoma and RA protocols  
7respectively . Although the treatment was 
administered according to the lymphoma protocol, 
our patient did not develop any serious side effects. 
RTX is an effective treatment of PV, but unfortunately, 
its use is restricted due to exorbitant costs. However, a 
30.3% decrease in the medication and hospital 
associated costs in comparison to 6 months before and 
6 months after RTX treatment of pemphigus and 
16pemhigoid disorders was reported.  Additionally, the 
improvement of the patient's quality of life with RTX 
has been priceless. Our patient had refractory oral PV 
and she was successfully treated with RTX without 
any life threatening side-effects. RTX improves 
patient's symptoms and quality of life. It appears safe 
and an effective treatment method particularly in 
refractory cases of PV. The cost is a major challenge 
with its use; therefore, medical schemes and hospital 
therapeutic committees should find ways to urgently 
reduce cost.
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